Dulaglutide
Also known as: Trulicity
Dulaglutide is a once-weekly GLP-1 receptor agonist approved in Australia as a prescription medicine for type 2 diabetes. Grey-market versions are not approved.
- Category
- Metabolic / GLP-1
- Reported half-life
- Reported ~5 days, supporting once-weekly dosing of the approved product
- Common forms
- Pre-filled single-dose injection pen (approved prescription product), Grey-market vials (not approved)
- Research status
- Prescription-only medicine in Australia (approved by the TGA for specified indications). Grey-market versions are not approved and sit outside the regulated supply chain.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Demonstrated in clinical trials to lower blood glucose in type 2 diabetes
- Reported cardiovascular outcome findings in certain trial populations
- Reported to reduce appetite and support modest weight change in trials
How it is reported to work
Dulaglutide is reported to mimic GLP-1, a gut hormone that stimulates insulin release when blood sugar is high, suppresses glucagon and slows gastric emptying. These actions are reported to improve glucose control. These mechanisms are supported by large human clinical trials, unlike many unapproved research peptides.
Background
Dulaglutide is a once-weekly GLP-1 receptor agonist sold under the brand name Trulicity. It is an approved prescription medicine in Australia for type 2 diabetes, backed by large human trials, unlike most unapproved research peptides catalogued on this site. This page is educational and is not medical advice; it does not recommend use.
What the research shows
Dulaglutide has been evaluated in the AWARD programme (diabetes) and the REWIND cardiovascular outcomes trial. These randomised trials reported effects on glucose control and explored cardiovascular outcomes. Results differ between individuals, and the medicine carries side effects requiring professional monitoring.
| Programme | Focus | Outcome reported |
|---|---|---|
| AWARD | Type 2 diabetes | Improved glucose control |
| REWIND | Cardiovascular | Outcome findings in study population |
What people use it for (regulated indications)
In Australia, dulaglutide is prescribed for type 2 diabetes in eligible patients, as determined by a healthcare professional based on individual assessment.
Things to be aware of
There is an important difference between the TGA-approved product and grey-market “dulaglutide” sold outside the regulated supply chain, whose purity, identity and content cannot be assured, which is why independent testing is discussed in this community. Reported side effects include nausea and other gastrointestinal effects, with rarer serious reactions possible, and individual responses vary. Because dulaglutide is prescription-only, it should only be used under medical supervision by a qualified healthcare professional who can assess suitability. This article explains what dulaglutide is and what the evidence shows; it is educational, does not recommend any dose, and does not direct anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in trials to lower HbA1c and fasting blood glucose in type 2 diabetes
- Commonly reported reduction in appetite and food intake
- Reported modest weight loss in many study participants
- Once-weekly dosing reported as convenient versus daily injectables
- Cardiovascular outcome findings reported in the REWIND trial population
Common side effects
- Nausea, especially when starting or increasing dose
- Diarrhoea and vomiting
- Reduced appetite and early satiety
- Indigestion, bloating or abdominal discomfort
- Injection-site redness or itching
Rare / serious side effects
- Pancreatitis (severe persistent abdominal pain reported)
- Gallbladder problems including gallstones
- Severe hypoglycaemia when combined with insulin or sulfonylureas
- Acute kidney injury, often linked to dehydration from vomiting
- Serious allergic or hypersensitivity reactions
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Dulaglutide. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported off-label use solely for weight loss via grey-market vials outside medical supervision
- Reported dose escalation faster than the labelled titration, increasing nausea and vomiting
- Reported use of unverified grey-market product with uncertain identity, dose and sterility
- Reported combining with insulin or sulfonylureas without monitoring, raising hypoglycaemia risk
- Reported continued use despite severe dehydration, risking kidney harm
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Appetite and glucose effects are reported within days, with weight and HbA1c changes reported building over weeks to months.
First effects
Reduced appetite and possible nausea reported within days
Noticeable change
Reported appetite suppression and early glucose changes
Clear results
Reported HbA1c reduction and weight change over months
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Dulaglutide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported approved labelling starts at 0.75 mg per week, with reported titration to 1.5 mg, 3 mg or 4.5 mg per week |
| Frequency | Reported as once weekly |
| Cycle length | Reported as ongoing maintenance rather than cycled, per the approved product |
Commonly reported as a once-weekly injection titrated upward over weeks per the approved product label; reported as ongoing rather than cycled. This is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Metformin
Reported used together in type 2 diabetes for complementary glucose lowering
Reported discussed alongside GLP-1 agonists for additive appetite and weight effects
Reported compared or transitioned between as newer incretin agents
Safety notes
As a prescription-only medicine, dulaglutide should only be used under the supervision of a qualified healthcare professional who can assess suitability and monitor side effects such as nausea and gastrointestinal upset, plus rarer serious reactions. Grey-market versions are not TGA-approved and their quality cannot be assured. Do not use any version without medical guidance.